Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction
Background Preeclampsia is associated with placental ischemia/hypoxia and secretion of
soluble fms-like tyrosine kinase 1 and soluble endoglin into the maternal circulation. This
causes widespread endothelial dysfunction that manifests clinically as hypertension and
multisystem organ injury. Recently, small molecule inhibitors of hypoxic inducible factor 1α
have been found to reduce soluble fms-like tyrosine kinase 1 and soluble endoglin
secretion. However, their safety profile in pregnancy is unknown. Metformin is safe in�…
soluble fms-like tyrosine kinase 1 and soluble endoglin into the maternal circulation. This
causes widespread endothelial dysfunction that manifests clinically as hypertension and
multisystem organ injury. Recently, small molecule inhibitors of hypoxic inducible factor 1α
have been found to reduce soluble fms-like tyrosine kinase 1 and soluble endoglin
secretion. However, their safety profile in pregnancy is unknown. Metformin is safe in�…